HomeFileStructural heart disease

Structural heart disease

Hypertrophic Cardiomyopathy: Analyzing a Historical Series

75% of patients with hypertrophic Cardiomyopathy present symptoms. An important group responds very well to pharmacological treatment...

Avatar Trial: Is It Time to Use Surgical Aortic Valve Replacement in Asymptomatic Patients?

It is still unclear whether surgical aortic valve replacement (SAVR) is beneficial in asymptomatic patients with severe...

Should We Use Left Atrial Appendage Occlusion More Frequently? What Real-Life Data Are Available?

Left atrial appendage occlusion (LAAO) is an alternative to prevent atrial fibrillation stroke mainly used in patients...

ACC 2022 | CLASP TR Study: Tricuspid Valve Repair with the PASCAL Device

The study included 65 patients who received endovascular treatment of the tricuspid valve with the PASCAL device....

ACC 2022 | ADAPT-TAVR: Endoxaban Is Not Superior to DAPT After TAVR

DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent...

ACC 2022 | APOLLO

Lipoprotein a (Lp a) is an important risk factor for atherothrombosis and atherosclerotic cardiovascular disease, but it...

Same-Day Discharger After TAVR: Are We There Yet?

Same-day discharge (SDD) has been shown to be effective in angioplasties and some peripheral procedures, but the...

TRICENTO: Promising Results for Severe Tricuspid Valve Regurgitation

Difficult to treat, tricuspid valve failure poses great medical challenge. In addition, the mortality rate of surgical...